C4 Therapeutics, Inc. (CCCC) Misses Q2 EPS by 1c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q2 EPS of ($0.73), $0.01 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $5.39 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals